Trial Profile
A Global Phase 3 Double-Blind Placebo-Controlled Safety and Efficacy Study of Oral Dimebon [dimebolin] in Patients With Mild-to-Moderate Alzheimer's Disease (CONNECTION).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Latrepirdine (Primary)
- Indications Alzheimer's disease
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms CONNECTION
- 16 Nov 2011 Additional locations added as reported by European Clinical Trials Database (EudraCT2008-000095-25).
- 14 Jul 2010 Results will be presented at the 2010 International Conference on Alzheimer's Disease (ICAD 2010).
- 14 Jul 2010 Trial design details were presented at the 2010 International Conference on Alzheimer's Disease (ICAD 2010).